$CMRA News
Last published 2y ago
- 2y agoCMRAComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionGlobeNewswireWOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a proprietary drug-delivery technology to improve
- 2y agoCMRAComera Life Sciences Announces Process Exploring Strategic AlternativesGlobeNewswireWOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines to improve
- 3y agoCMRAComera Life Sciences Appoints Dorothy Clarke to Board of DirectorsGlobeNewswireWOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and
- 3y agoCMRAComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business HighlightsGlobeNewswire– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera's global patent portfolio, broadening
- 3y agoCMRAComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceGlobeNewswireWOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and
- 3y agoCMRAComera Life Sciences Announces the Completion of $4.1 Million Private PlacementGlobeNewswireWOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and
- 3y agoCMRAComera Life Sciences Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing CapabilitiesGlobeNewswireData published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies WOBURN, Mass., Aug. 16, 2023 (GLOBE
- 3y agoCMRAComera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business HighlightsGlobeNewswire– Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera's request for the continued
- 3y agoCMRAComera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ PlatformGlobeNewswireWOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and
- 3y agoCMRAComera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore ExcipientsGlobeNewswire– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs – WOBURN, Mass., July 20, 2023
- 3y agoCMRAComera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business HighlightsGlobeNewswire– Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab), highlighted by
- 3y agoCMRAComera Life Sciences to Participate in Four Upcoming ConferencesGlobeNewswireWOBURN, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) ("Company" or "Comera"), a life sciences company developing a new generation of bio-innovative biologic medicines to
- 3y agoCMRAHDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS. ROMAN FLECK AND NEAL I. MUNI TO BOARD OF DIRECTORSPR NewswireAppointment of veteran industry executives adds broad experience to HDAX team. MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing
- 3y agoCMRAComera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient TechnologyGlobeNewswire– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™ platform – – Patent granted in South Korea and Notice of Allowance received
- 3y agoCMRAComera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business HighlightsGlobeNewswire– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody
- 3y agoCMRAComera Life Sciences to Present at 22nd Annual PepTalk ConferenceGlobeNewswireWOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) ("Company" or "Comera"), a life sciences company developing a new generation of bio-innovative biologic medicines to
- 3y agoCMRAComera Life Sciences to Present at Upcoming Biotech Showcase Investor ConferenceGlobeNewswireWOBURN, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery,
- 3y agoCMRAComera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq RulesGlobeNewswireWOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access,
- 3y agoCMRAComera Life Sciences to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor ConferenceGlobeNewswireWOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access,
- 4y agoCMRAComera Life Sciences Reports Financial Results for Third Quarter 2022 and Business HighlightsGlobeNewswire– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody
- 4y agoCMRAComera Life Sciences Appoints Janice Marie McCourt as Chief Business OfficerGlobeNewswireWOBURN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery,
- 4y agoCMRAComera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 StudyGlobeNewswireWOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access,
- 4y agoCMRAComera Life Sciences Expands Woburn OperationsGlobeNewswireElected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of
- 4y agoCMRAComera Life Sciences Announces Up To $15 million Purchase Agreement with Arena Business SolutionsGlobeNewswireWOBURN, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) ("Company" or "Comera"), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and c
- 4y agoCMRAComera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing SummitGlobeNewswireWOBURN, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) ("Company" or "Comera"), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and c
- 4y agoCMRAComera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022GlobeNewswireWOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today provi
- 4y agoCMRAComera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore ExcipientGlobeNewswireWOBURN, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, announced f
- 4y agoCMRAComera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore PlatformBusiness WireComera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Paten
- 4y agoCMRAComera Life Sciences Appoints Michael Campbell as Executive Vice President and Chief Financial OfficerBusiness WireComera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the appointment of Michael Campbell as Execut
- 4y agoCMRAOTRAOTRAUOTRAWComera Life Sciences Debuts as Publicly Traded Company Focused on Transforming BiologicsBusiness Wire– Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" –